Tirzepatide vs Semaglutide: Dual Agonist vs GLP-1, Head-to-Head

Tirzepatide and semaglutide are the two dominant incretin therapies, and unlike most peptide comparisons this one has a genuine head-to-head randomized trial behind it. Tirzepatide (tirzepatide, Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist; semaglutide (semaglutide, Ozempic/Wegovy/Rybelsus) is a single GLP-1 receptor agonist. Both are FDA-approved drugs — this comparison is informational, and decisions about either belong with a prescribing clinician.

TL;DR: Tirzepatide activates two incretin receptors (GIP and GLP-1); semaglutide activates one (GLP-1). In the SURPASS-2 head-to-head, tirzepatide beat semaglutide 1 mg on HbA1c and weight. Tirzepatide reaches higher weight loss (~22.5% vs ~15%, separate trials); semaglutide has the stronger cardiovascular-outcomes data (SELECT) and an oral form. Both are FDA-approved, not WADA-banned.

Medical & affiliate disclosure: This article is for educational and informational purposes only and is not medical advice. Both tirzepatide and semaglutide are FDA-approved prescription medications; do not start, stop, switch, or dose either without a qualified clinician. Compounded versions are subject to active FDA enforcement. VialBase may earn a commission from qualifying purchases made through vendor links on this page; this does not influence the research summarized here.

At a Glance

The core distinction is one receptor vs two. Here is the side-by-side the rest of the article expands on. Note that most figures come from separate trials; the only true head-to-head is SURPASS-2.

The honest framing: tirzepatide tends to win on magnitude of weight loss and glycemic control, while semaglutide has the deeper long-term cardiovascular-outcome evidence and an oral option. The one apples-to-apples comparison (SURPASS-2) favored tirzepatide, but it used semaglutide’s diabetes dose (1 mg), not the higher obesity dose (2.4 mg).

What Is Tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide and the first-in-class dual incretin agonist — an “imbalanced” agonist that activates GIP receptors with high potency and GLP-1 receptors with moderate potency. A C-20 fatty-diacid acylation enables albumin binding, extending its half-life to ~5 days for once-weekly dosing, and an Aib substitution at position 2 provides DPP-4 resistance.

Its mechanism combines two complementary metabolic pathways: GIP-receptor activation enhances glucose-dependent insulin secretion, improves adipose insulin sensitivity, and contributes to appetite regulation through pathways partly distinct from GLP-1; GLP-1-receptor activation suppresses appetite, delays gastric emptying, enhances insulin secretion, and suppresses glucagon (the same axis as semaglutide). Together these produce greater insulin secretion, superior glycemic control, and more weight loss than either pathway alone; GIP signaling may also attenuate GLP-1-mediated nausea, potentially improving tolerability.

The clinical evidence is substantial (over 1,870 PubMed publications). The headline obesity result is SURMOUNT-1: in 2,539 adults without type-2 diabetes, tirzepatide 15 mg produced 22.5% mean body-weight loss versus 2.4% placebo at 72 weeks — the highest weight loss reported for any anti-obesity medication at the time (Jastreboff et al., 2022, PMID 35658024). In adults with T2D and obesity, SURMOUNT-2 showed 14.7% weight loss and 2.1% HbA1c reduction at 72 weeks (Garvey et al., 2023, PMID 37385275). Withdrawal data (SURMOUNT-4) confirmed that continued treatment is needed to maintain the loss (Aronne et al., 2024, PMID 38078870).

What Is Semaglutide?

Semaglutide is a 31-amino-acid GLP-1 receptor agonist — a modified analog of human GLP-1(7-36) with ~94% sequence homology, engineered with an Aib substitution at position 2 and a C-18 fatty-diacid chain for albumin binding and a ~7-day half-life. It is the most widely prescribed incretin therapy globally, with over 4,500 PubMed publications, and is available as Ozempic (T2D), Wegovy (weight management), and Rybelsus (oral semaglutide for T2D) — the oral option tirzepatide lacks.

Its mechanism is the GLP-1 half of tirzepatide’s: it stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite via hypothalamic signaling. It has no GIP activity.

The clinical evidence is deep and, importantly, includes long-term cardiovascular outcomes — semaglutide’s distinguishing strength. STEP 1 produced 14.9% body-weight loss versus placebo at 68 weeks in adults with overweight/obesity (Wilding et al., 2021, PMID 33567185); STEP 2 studied semaglutide 2.4 mg in adults with overweight/obesity and T2D (Davies et al., 2021, PMID 33667417); and SELECT — the landmark result — showed a 20% reduction in major adverse cardiovascular events in overweight/obese adults with established cardiovascular disease but without diabetes (Lincoff et al., 2023, PMID 37952131), a hard-outcome result tirzepatide does not yet match. STEP 8 showed semaglutide 2.4 mg produced greater weight loss than liraglutide 3.0 mg (Rubino et al., 2022, PMID 35015037).

The Core Difference: One Receptor vs Two

This is the section that actually settles the comparison.

GIP + GLP-1 vs GLP-1 alone

Semaglutide is a pure GLP-1 agonist. Tirzepatide adds GIP-receptor agonism on top of GLP-1. Adding the second incretin receptor is the entire reason tirzepatide tends to outperform on weight and glucose: GIP contributes its own insulinotropic and appetite-regulating effects, and the two pathways together drive greater insulin secretion and weight loss than GLP-1 alone. A subtler benefit is tolerability: GIP signaling may partially offset GLP-1-mediated nausea, which is part of why tirzepatide’s GI side effects can be milder despite greater efficacy.

The one true head-to-head: SURPASS-2

Most “tirzepatide vs semaglutide” numbers come from separate trials, which is not a fair comparison. The exception is SURPASS-2, a randomized head-to-head in type-2 diabetes: all tirzepatide doses were superior to semaglutide 1 mg, with tirzepatide 15 mg achieving a greater HbA1c reduction (-2.46% vs -1.86%) and greater weight loss (-12.4 kg vs -6.2 kg) (Frías et al., 2021, PMID 34170647).

Evidence-tier caveat — read this before quoting the numbers. SURPASS-2 compared tirzepatide against semaglutide 1 mg, the type-2-diabetes dose. The obesity dose of semaglutide is 2.4 mg (Wegovy). So SURPASS-2 demonstrates tirzepatide’s superiority at the diabetes dose, and it does not establish a head-to-head result at the higher obesity dose. The often-quoted “22.5% vs 14.9%” weight-loss gap is a cross-trial comparison of SURMOUNT-1 versus STEP 1 — different populations, different protocols — and should be presented as such.

Cardiovascular outcomes — semaglutide’s edge

Weight loss is a surrogate; hard cardiovascular outcomes are what change guidelines. Here semaglutide leads: SELECT showed a 20% MACE reduction in non-diabetic CVD patients (Lincoff et al., 2023, PMID 37952131). Tirzepatide’s cardiovascular-outcomes evidence is still emerging. For a patient whose priority is documented CV-event reduction, that distinction matters.

Research Comparison

The honest summary: tirzepatide wins on weight-loss magnitude and glycemic control (with one real head-to-head at the diabetes dose); semaglutide wins on depth of long-term cardiovascular-outcome data and offers an oral form.

Dosing & Administration

These are prescribing-label-derived figures for context only — actual dosing is set by a clinician. Both are once-weekly subcutaneous injections (semaglutide also has a daily oral form), titrated slowly to limit GI side effects.

Tirzepatide: 2.5 mg (weeks 1-4, starter — not therapeutic) → 5 → 7.5 → 10 → 12.5 → up to 15 mg maintenance, escalating roughly every 4 weeks as tolerated. Once weekly, subcutaneous. Injectable only.

Semaglutide: Ozempic/Wegovy 0.25 mg starter (4 weeks) → 0.5 → 1.0 → 1.7 → up to 2.4 mg (Wegovy target) once weekly, subcutaneous. Rybelsus (oral): 3 → 7 → 14 mg daily on an empty stomach.

The slow titration on both is deliberate: escalating too fast is the main driver of intolerable nausea, and tirzepatide’s titration is generally even more gradual.

Side Effects & Safety

Both share the GLP-1-class side-effect profile, dominated by gastrointestinal effects, with one shared boxed warning.

Common (both): nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, injection-site reactions. Nausea is typically the dose-limiting effect; tirzepatide’s is often described as somewhat milder (25-33%), possibly because GIP offsets GLP-1-mediated nausea.

Serious but rare (both): thyroid C-cell tumors — boxed warning (from rodent studies), contraindicated with personal/family history of medullary thyroid carcinoma (MTC) or MEN2; pancreatitis (<0.2%); gallbladder disease with rapid weight loss; hypoglycemia (mainly with insulin/sulfonylureas); dehydration-related acute kidney injury.

Contraindications (both): personal/family history of MTC; MEN2; known hypersensitivity; pregnancy/breastfeeding.

Legality

Unlike most peptides VialBase covers, both are FDA-approved prescription drugs. Tirzepatide — Mounjaro (T2D, 2022) and Zepbound (weight, 2023); Semaglutide — Ozempic (2017), Wegovy (2021), Rybelsus (2019). Neither is WADA-prohibited with a valid prescription. Both have been produced by compounding pharmacies under the FDA 503A shortage framework, but the FDA has moved to restrict compounding as shortages resolved (with litigation ongoing into 2026); compounded tirzepatide is significantly more restricted than compounded semaglutide, and neither compounded version is the FDA-approved product.

Which Should You Consider?

This is a clinical decision — the framing below is informational, not a recommendation, and applies to the FDA-approved products under medical supervision.

• Maximum weight loss → tirzepatide generally has the edge on magnitude, and the one head-to-head (SURPASS-2) favored it at the diabetes dose.
• Glycemic control in T2D → tirzepatide (superior HbA1c vs semaglutide 1 mg, SURPASS-2).
• Documented cardiovascular-event reduction → semaglutide (SELECT hard-outcome data).
• Oral option → semaglutide (Rybelsus); tirzepatide is injectable only.
• Tolerability concern / prior GLP-1 nausea → possibly tirzepatide (GIP may offset nausea; individual).

The honest bottom line: tirzepatide for greater weight/glucose effect, semaglutide for the deeper cardiovascular-outcome evidence and the oral option — and the choice belongs with a prescriber.

Where to Buy

These are prescription medications — the appropriate route is a licensed clinician and a pharmacy dispensing the FDA-approved branded products (Mounjaro/Zepbound, Ozempic/Wegovy/Rybelsus). Compounded versions exist but are subject to active FDA enforcement and the quality/legal caveats above; they are not the approved product. VialBase does not position these as research chemicals in the way it does unapproved peptides.

Frequently Asked Questions

What is the difference between tirzepatide and semaglutide? Tirzepatide activates two incretin receptors — GIP and GLP-1 — while semaglutide activates only GLP-1. The added GIP activity is why tirzepatide tends to produce greater weight loss and better glucose control. Brand-wise, tirzepatide is Mounjaro/Zepbound and semaglutide is Ozempic/Wegovy/Rybelsus.

Is tirzepatide better than semaglutide for weight loss? On magnitude, generally yes — tirzepatide reached ~22.5% mean weight loss in SURMOUNT-1 versus ~14.9% for semaglutide in STEP 1, and the one head-to-head trial (SURPASS-2) favored tirzepatide. But the big weight-loss gap is a cross-trial comparison, and SURPASS-2 used semaglutide’s lower diabetes dose (1 mg), not the 2.4 mg obesity dose, so it is not a perfectly fair comparison.

Which has better cardiovascular evidence? Semaglutide. The SELECT trial showed a 20% reduction in major adverse cardiovascular events in overweight/obese adults with cardiovascular disease but without diabetes (Lincoff et al., 2023). Tirzepatide’s cardiovascular-outcomes data are still emerging, so for documented CV-event reduction semaglutide currently has the stronger evidence.

Does tirzepatide have fewer side effects than semaglutide? Both cause GI side effects (nausea, diarrhea, constipation) as the dominant class effect. Tirzepatide’s nausea is often described as somewhat milder, possibly because GIP activity offsets GLP-1-mediated nausea, and its trials showed somewhat lower severe-GI rates despite greater weight loss. Both carry a boxed warning for thyroid C-cell tumors and the same core contraindications. Individual tolerability varies.

Can you take tirzepatide and semaglutide together? No — they are alternatives, not a stack. They act on overlapping pathways (both hit GLP-1), so combining them is not additive and is not recommended. Patients sometimes switch from semaglutide to tirzepatide for greater effect, under medical supervision, but they are not used concurrently.

Are tirzepatide and semaglutide legal? Both are FDA-approved prescription medications and are not prohibited by WADA when used with a valid prescription. Compounded versions have existed under the drug-shortage framework, but the FDA has moved to restrict compounding (with ongoing litigation in 2026), and compounded tirzepatide is more restricted than compounded semaglutide. Use the FDA-approved product under a clinician’s care.

Does semaglutide come as a pill? Yes — Rybelsus is oral semaglutide, FDA-approved for type-2 diabetes, taken daily on an empty stomach. Tirzepatide has no oral form and is injectable only. For patients who prefer or need an oral option, that is a point in semaglutide’s favor.

References

• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID 35658024 — SURMOUNT-1: 22.5% mean weight loss with tirzepatide 15 mg at 72 weeks.
• Garvey WT, et al. Tirzepatide once weekly for obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PMID 37385275 — 14.7% weight loss in T2D + obesity.
• Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID 34170647 — SURPASS-2, the head-to-head: tirzepatide superior to semaglutide 1 mg.
• Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48. PMID 38078870 — continued treatment needed to maintain loss.
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID 33567185 — STEP 1: 14.9% weight loss with semaglutide 2.4 mg.
• Davies M, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID 33667417 — STEP 2.
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID 37952131 — SELECT: 20% MACE reduction.
• Rubino DM, et al. Weekly Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA. 2022;327(2):138-150. PMID 35015037 — STEP 8.

Citations verified against the NCBI PubMed API, with each trial ID confirmed to the correct drug (this pairing is prone to cross-entity contamination): SURMOUNT to tirzepatide, STEP/SELECT to semaglutide, SURPASS-2 as the genuine head-to-head. The SURMOUNT-5 obesity head-to-head is referenced qualitatively rather than tied to a specific PMID, in line with VialBase citation policy.